PeptiDrive-LNDP™

A NOVEL, FAST-ACTING PEPTIDE FOR COGNITIVE FUNCTION

For thousands of years, people have been drinking fermented milk for its reputed health benefits. But only in the 21st century was it discovered that this drink has specific effects on cognition. Food derived peptides have become an increasing interest for scientists due to their potential benefits to human health. Food derived bioactive peptides have been observed to support collagen production and skin health, promote muscle synthesis, and support cardiovascular function. It has now been observed that several peptides within milk have shown to be effective in promoting cognitive function.1 In particular, one 19 amino acid peptide derived from casein was observed to be promote cognitive function through a specific mode of action.

Developed through a proprietary enzymatic hydrolysis of casein, this 19 amino acid peptide called PeptiDrive-LNDP™, was hypothesized to support the cognitive function in humans due to in vivo research showing its ability to enhance the expression of BDNF, a protein that supports neuroplasticity and neuron survival.* Additionally, it was also observed to promote the release of acetylcholine within the brain. Supported by three clinical studies demonstrating its cognitive performance benefits, PeptiDrive-LNDP™ could emerge as the next food-derived bioactive peptide driving growing interest in peptides that help support focus, mental performance, and productivity in everyday life.

PeptiDrive-LNDP™ Benefits:

  • ✅ Supports cognitive function*
  • ✅ Enhances processing speed*
  • ✅ Supports executive function*
  • ✅ Benefits memory*
  • ✅ Supports attention and concentration*

Researched benefits

PeptiDrive-LNDP™ has been researched in three randomized, double-blind, placebo-controlled clinical trials, showing it has both immediate and longer-term effects.

  • 8-week study: A fermented milk drink containing 2.4 mg/day of PeptiDrive-LNDP™ supported cognitive functions such as attention and delayed memory in healthy older adults aged 50-70 who reported experiencing forgetfulness.*2
  • 12-week study: Taking 2.1 mg/day PeptiDrive-LNDP™ in tablet form benefited cognitive abilities—including attention, concentration, and speed of information processing—among healthy middle-aged and senior adults.*3
  • Single-dose study: A single dose of 2.4 mg of the ingredient supported processing speed and executive function in healthy men aged 30-59 undertaking a mentally demanding task. The authors noted this could benefit cognitive functions such as memory, attention, concentration, and information processing in daily life.*1

STATUS

Kosher Halal Gluten Free Self Affirmed GRAS

FUNCTIONS

Cognitive E-Gaming Sports Nutrition

DELIVERY FORMATS

Tablets

MECHANISM OF ACTION

Animal research suggests PeptiDrive-LNDP™:

  • Promotes the expression of BDNF.*³ Not only does this protein help neurons develop and grow, it strengthens the synaptic connections between neurons—vital for learning and memory.*

  • Enhances the expression of nerve growth factor (NGF) and neutrotrophin-3 (NT-3), both of which help neurons develop, differentiate, and survive, helping maintainhealthy brain structure and function.* 

  • May promote the release of acetylcholine, a neurotransmitter important for learning, memory, attention, and overall cognitive processing.* 

SAFETY

PeptiDrive-LNDP™is derived fromprotein found in milk,casein,whichhas beensafelyconsumed in the food supplyfor thousands of years.Itis self-affirmedGRAS,and clinical researchhasrevealed nooccurrences ofside effectsor adverse eventsafter12 weeksof daily use.However, PeptiDrive-LNDP™should not be consumed by those with milk allergies.

References

  1. Sasai M, Kato M, Ohsawa K, Sashihara K, Nakamura Y, Kaneko T.BiosciBiotechnolBiochem. 2021;85(4):948-956. doi:10.1093/bbb/zbaa117
  2. Ohsawa K, Nakamura F, Uchida N, Mizuno S,YokogoshiH.Int J Food SciNutr. 2018;69(3):369-376. doi:10.1080/09637486.2017.1365824
  3. Nakamura F, Ohsawa K, Nakamura Y,SawabeA, Miura N, Okuda J.JpnPharmacolTher.2017;45:1303-1314.
  4. Nakamura F, Ohsawa K, Sato K, Nakamura Y.PharmacometŌōYakuri0300-8533. 2018;95(1/2):9.